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Abstract 20 
The in vitro dipeptidyl peptidase IV (DPP-IV) inhibitory activity of a whey protein hydrolysate 21 
(WPH) generated with a food-grade pancreatic enzyme preparation was studied. The 50 % 22 
inhibitory concentration (IC50) value in the presence of WPH was 1.34 ± 0.11 mg.mL
-1
. 23 
Ultrafiltration (UF) fractionation of WPH allowed enrichment in DPP-IV inhibitory peptides. The 24 
permeates generated by UF through 5 and 2 kDa membranes along with the hydrophilic fraction 25 
isolated by solid-phase extraction were significantly more potent (P < 0.05) DPP-IV inhibitors 26 
than WPH. These samples respectively had IC50 values of 0.95 ± 0.16, 0.48 ± 0.01 and 1.11 ± 27 
0.09 mg.mL
-1
. Simulated gastrointestinal digestion (SGID) of WPH resulted in an increased DPP-28 
IV inhibitory potency (IC50 value of 1.02 ± 0.05 mg.mL
-1
). Competitive inhibition of DPP-IV was 29 
observed with WPH and all its fractions, indicating a direct interaction of the bioactive peptides 30 
therein with the active site of DPP-IV. Combinations of sitagliptin, a conventional drug-inhibitor 31 
of DPP-IV, and whey-derived peptides resulted in an additive effect on DPP-IV inhibition. 32 
 33 
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1. Introduction 37 
Worldwide estimates indicate that 366 million people will be affected by diabetes in 2030 38 
(WHO, 2006). Different strategies are being used to prevent/treat type 2 diabetes (T2D), they 39 
include treatment with various anti-diabetic medications. Changes in the diet and lifestyle, and 40 
regular participation in physical exercise have been recommended as a means to help in the 41 
management of T2D (Bantle et al., 2008; Hawley & Gibala, 2012; Mensink et al., 2003). In the 42 
presence of glucose, incretins, including glucose dependent insulinotropic polypeptide (GIP) and 43 
glucagon-like peptide-1 (GLP-1), can influence insulin secretion from pancreatic beta cells 44 
(Drucker, 2006; Tulipano, Sibilia, Caroli, & Cocchi, 2011). Enzymatic degradation of these 45 
hormones by DPP-IV results in a significant reduction in their in vivo levels. Therefore, another 46 
avenue being explored in the management of T2D is the utilisation of DPP-IV inhibitors (Lacroix 47 
& Li-Chan, 2012a; Nauck & El-Ouaghlidi, 2005; Scheen, 2010). Various DPP-IV inhibitory 48 
drugs, also termed gliptins, are currently being used as fasting and post-prandial serum glucose 49 
lowering agents. These include sitagliptin, the first DPP-IV drug inhibitor available on the 50 
market. Classical insulin secretagogues (i.e sulfonylureas) have been associated with adverse 51 
effects such as hypoglycemia and weight gain. However, in diabetic subjects, gliptins can 52 
stimulate insulin secretion in the presence of glucose, this reduces the risk of hypoglycaemia and 53 
weight gain (Herman, Stein, Thornberry, & Wagner, 2007; Scheen, 2010). 54 
Dietary intake of milk proteins and milk protein hydrolysates has been shown to affect several 55 
biomarkers of diabetes including postprandial glycaemia and insulin secretion in humans 56 
(Manders et al., 2006b; Morifuji et al., 2010; Power, Hallihan, & Jakeman, 2009; Tremblay & 57 
Gilbert, 2009). The potential of milk-derived peptides to act as DPP-IV inhibitors has been 58 
demonstrated (Lacroix & Li-Chan, 2012a; Nongonierma & FitzGerald, 2013; Tulipano et al., 59 
2011; Uchida, Ohshiba, & Mogami, 2011; Uenishi, Kabuki, Seto, Serizawa, & Nakajima, 2012). 60 
A DPP-IV inhibitory peptide present in a tryptic digest of -lactoglobulin was shown to decrease 61 
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blood glucose level in mice following an oral glucose tolerance test (Uchida et al., 2011). 62 
Similarly, a casein-derived peptide (Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu) isolated from Gouda-type 63 
cheese caused a reduction of blood glucose level in rats following a glucose challenge (Uenishi et 64 
al., 2012). To date, most studies have investigated the potential role of milk peptides for their 65 
insulinotropic and blood glucose regulation properties. However, a limited amount of work 66 
appears to have been carried out studying the DPP-IV inhibitory properties of milk protein 67 
hydrolysates. DPP-IV inhibitors may act directly in the gastrointestinal tract, allowing an 68 
improved blood glucose homeostasis (Tulipano et al., 2011). Targeting DPP-IV inhibition using 69 
food-derived peptides could ultimately result in an increased half-life of the incretins. 70 
In drug development, it is common practice to evaluate drug-drug interactions in order to 71 
determine side/adverse effects. However, very little data is available in the literature describing 72 
food-drug interactions. Food-drug interactions may have implications in the pharmacokinetics of 73 
a drug or the nutritional status of food components. Food may affect bioavailability, distribution, 74 
metabolism and elimination of drug molecules. It has been suggested that bioactive food-derived 75 
compounds, including polyphenols and bioactive peptides, may interact with drugs (Boullata, 76 
2010; Genser, 2008). Some data is available on the effect of food-drug interactions on metabolic 77 
enzymes. It has been shown that grape fruit juice furanocoumarin can selectively inhibit intestinal 78 
cytochrome P450 (CYP) 34A enzymes (Paine et al., 2006; Paine et al., 2008). These enzymes are 79 
drug metabolising enzymes, the inhibition of which may result in an increased exposure to a drug 80 
which in turn may lead to adverse effects in humans (Genser, 2008). The outcomes of different 81 
pharmacokinetic studies suggest minor risks of drug-drug interactions in the specific case of 82 
sitagliptin (Herman et al., 2007; Scheen, 2010). It has been reported that gliptins have a good 83 
bioavailability which is not affected by food intake. In healthy volunteers, it was shown that 84 
administration of 100 mg sitagliptin with a high fat breakfast did not modify its pharmacokinetics 85 
suggesting that no specific interaction occurred with food in this case (Bergman et al., 2007). 86 
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However, no studies to our knowledge report on potential sitagliptin-peptide interaction. 87 
The aim of this study was to investigate the potential of a whey-derived protein hydrolysate 88 
(WPH) to act as a DPP-IV inhibitor. Fractionation was investigated as a means to enrich for the 89 
bioactive components within the hydrolysate. Simulated gastrointestinal digestion (SGID) was 90 
investigated to determine bioactive peptide stability to gastrointestinal enzymes. Finally, the 91 
effect of various combinations of sitagliptin and whey-derived peptides on DPP-IV activity was 92 
studied. 93 
2. Materials and methods 94 
2.1. Materials 95 
Trifluoroacetic acid (TFA), porcine DPP-IV (≥ 10 units/mg protein), para-nitroaniline (pNA), 96 
Gly-Pro-pNA, Tris(hydroxymethyl)aminomethane (TRIS), diprotin A (Ile-Pro-Ile) and sitagliptin 97 
were obtained from Sigma Aldrich (Dublin, Ireland). Trp-Val and Val-Ala were obtained from 98 
Bachem (Bubendorf, Switzerland). Hydrochloric acid (HCl), sodium hydroxide (NaOH), high 99 
performance liquid chromatography (HPLC) grade water and acetonitrile (ACN) were from 100 
VWR (Dublin, Ireland). The solid-phase extraction (SPE) cartridge Giga Tubes StrataX (33µm, 101 
85Å Polymeric RP 1 g / 12 mL) were obtained from Phenomenex (Cheshire, UK). The whey 102 
protein substrate (WP) was a whey protein isolate purchased from a commercial supplier 103 
(Carbery, Ballineen, Ireland). BC pepsin and Corolase PP were obtained from Biocatalysts 104 
(Wales, UK) and AB enzymes (Darmstadt, Germany), respectively. 105 
2.2. Hydrolysis of the whey protein substrate 106 
Hydrolysis of the whey protein substrate was carried out as described by Nongonierma & 107 
FitzGerald (2012). The starting whey protein substrate WP was suspended at 10 % (w/w) on a 108 
protein basis in water and dispersed under agitation at 50C for 1 h using an overhead stirrer 109 
(Heidolph RZR 1, Germany). A control sample without enzyme was removed from the protein 110 
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dispersion and maintained at 50°C for the duration of the hydrolysis reaction. WP was hydrolysed 111 
with Corolase PP at an enzyme to substrate ratio (E:S) of 1 % (w/w) at 50°C for 240 min. 112 
Hydrolysis was carried out at a constant pH of 7.0 using a pH Stat (Titrando 843, Tiamo 1.4 113 
Metrohm, Dublin, Ireland). The enzyme was inactivated by heating the hydrolysate samples at 114 
90°C for 20 min. Hydrolysates were freeze-dried (FreeZone 18L, Labconco, Kansas City, 115 
U.S.A.) and stored at -20°C until further analysis. 116 
2.3. SGID of WPH 117 
SGID of WHP was carried out according to Walsh et al. (2004). Briefly, the freeze-dried 118 
WPH was resuspended in water with gentle stirring at 2 % (w/v) on a protein basis at 37C for 30 119 
min. The sample was incubated at 37°C, pH 2.0 with pepsin at an E:S of 1% (w/w) for 90 min 120 
then at pH 7.5 with Corolase PP at an E:S of 2.5 % (w/w) for another 150 min. The enzyme was 121 
inactivated by heating at 90°C for 20 min and the samples were subsequently freeze-dried and 122 
stored at -20°C until utilisation. 123 
2.4. Fractionation of WPH 124 
The WPH hydrolysate was fractionated using a plate and frame UF unit (Sartoflow Alpha 125 
filtration system, Sartorius, Germany). Fractionation was carried out using membranes having 5 126 
and 2 kDa molecular weight cut-off (MWCO) values. UF was carried out sequentially by 127 
processing WPH through the 5 kDa membrane. The 5 kDa permeate was then ultrafiltered using a 128 
2 kDa membrane. The four fractions (permeates and retentates) collected were freeze-dried and 129 
stored at -20°C until utilisation. 130 
WPH was fractionated by SPE as described by Herraiz & Casal (1995) and Nongonierma & 131 
FitzGerald (2012). Briefly, WPH was resuspended in HPLC grade water at a concentration of 1 132 
% (w/v) and 40 mL was applied on the SPE cartridge. The SPE cartridge was connected to a 133 
vacuum (15 mmHg) manifold (Phenomenex, Cheshire, UK). The SPE cartridge was washed with 134 
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HPLC grade water (10 mL) to collect the hydrophilic fraction of WPH. This fraction was freeze-135 
dried and stored at -20°C until utilisation. 136 
2.5. Reverse-phase ultra-performance liquid chromatography and molecular mass distribution of 137 
peptides and proteins 138 
The starting substrate (WP) and corresponding hydrolysate (WPH) and UF and SPE fractions 139 
were analysed by liquid chromatography using an ultra-performance liquid chromatograph 140 
(UPLC Acquity - Waters, Dublin, Ireland) as described by Nongonierma & FitzGerald (2012). 141 
Each sample was analysed in duplicate and the chromatographic profiles obtained were similar. 142 
The molecular mass profiles of the proteins and peptides were determined by gel permeation 143 
chromatography using high performance liquid chromatography (GPC-HPLC) essentially as 144 
described by Spellman, O’ Cuinn & FitzGerald (2009). Each sample was analysed in duplicate 145 
and the chromatographic profiles obtained were similar. 146 
2.6. DPP-IV inhibition assay 147 
The test samples were dispersed in HPLC grade water at final concentrations ranging from 148 
12.5 × 10
-3
 to 12.5 µg.mL
-1
 for diprotin A and from 0.6 × 10
-2
 to 0.6 mg.mL
-1
 for the WPH, UF 149 
and SPE fractions and SGID sample. The DPP-IV inhibition assay was carried out as described 150 
by Lacroix & Li-Chan (2012b). Briefly, test samples (25µL) were pipetted onto a 96 well 151 
microplate (Sarstedt, Dublin, Ireland) containing the substrate Gly-Pro-pNA, (final concentration 152 
0.2 mM). The negative control contained 25µL of 100 mM Tris-HCl buffer pH 8.0 and the 153 
substrate Gly-Pro-pNA. The reaction was initiated by the addition of 50 µL DPP-IV (final 154 
concentration 0.0025 Units/mL). All the reagents and samples were diluted in 100 mM Tris-HCl 155 
buffer pH 8.0. Diprotin A was used as a positive control. Each sample was analysed in triplicate. 156 
The microplate was incubated at 37C for 60 min in a microplate reader (Biotek Synergy HT, 157 
Winoosky, VT, USA), absorbance of the released pNA was monitored at 405 nm. The IC50 158 
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values for DPP-IV were determined by plotting the percentage inhibition as a function of the 159 
concentration of test compound. The mode of inhibition of the different samples was investigated 160 
using Lineweaver and Burk analysis. The initial rate of the reaction (pNA released from Gly-Pro-161 
pNA) was measured at different Gly-Pro-pNA final concentrations ranging between 0.200 and 162 
0.600 mM in the presence and absence of inhibitors (diprotin A, WPH, UF and SPE fractions and 163 
SGID sample) at their IC50 concentration. Km (determined without inhibitor) or Kapp (in the 164 
presence of inhibitor) and Vmax values were determined from the double reciprocal plots 165 
(Nongonierma & FitzGerald, 2012; Spanou et al., 2012). 166 
Interactions between sitagliptin and diprotin A, WPH or two whey-derived dipeptide inhibitors 167 
(Trp-Val and Val-Ala) of DPP-IV were studied. This was carried out by determining the extent of 168 
DPP-IV inhibition in the presence of 0.006 or 0.031 ng.mL
-1
 (final concentration) stagliptin. The 169 
final concentrations tested ranged from 12.5 × 10
-3
 to 12.5 µg.mL
-1
 for diprotin A and were from 170 
0.6 × 10
-2
 to 0.6 mg.mL
-1
 for WPH, Trp-Val and Val-Ala. The dose response curves obtained for 171 
diprotin A, WPH, Trp-Val or Val-Ala with or without added sitagliptin were compared. The 172 
apparent IC50 in the presence of 0.006 ng.mL
-1
 (final concentration) sitagliptin was determined. 173 
2.7. Statistical analysis 174 
Data analysis was carried out with a one way ANOVA for means comparison. A Student 175 
Newman-Keuls test at a significance level P < 0.05 was performed following the ANOVA using 176 
SPSS (version 9, SPSS Inc., Chicago, IL, USA). Experimental data obtained with the Lineweaver 177 
and Burk plot were fitted by linear regression using SPSS. 178 
3. Results 179 
3.1. Physicochemical properties of the WPH 180 
The molecular weight distribution profiles of the WP and the corresponding WPH along with 181 
its 5 and 2 kDa UF retentates and permeates are shown in Fig. 1. The unhydrolysed starting 182 
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material, as expected, consisted of relatively large molecular weight proteins, with more than 80 183 
% of the sample being greater than 10 kDa. In contrast, the WPH sample contained 25.6 % 184 
proteinaceous material > 10 kDa. Upon hydrolysis, the proteins were broken down, resulting in a 185 
reduction in the molecular weight of the components within the WP substrate. Analysis of the 186 
WPH UF treated samples shows that the higher molecular weight components were retained in 187 
the UF membranes resulting in an enrichment of lower molecular weight peptides (< 5 and 2 188 
kDa) in the permeates (Fig. 1). 189 
SGID of the WP hydrolysate was carried out to assess the stability of the peptides to 190 
gastrointestinal enzymes. Numerous peptide peaks can be seen on the RP profile of WPH (Fig. 191 
2A). Modification of the peptide composition of WPH occurred during SGID as can be seen from 192 
the RP profiles (Fig. 2B). SGID of WPH mainly resulted in the disappearance of some of the 193 
peptide peaks eluting at higher retention times (> 15 min). In addition some peptide peaks were 194 
more abundant in the hydrophilic region of the RP profile for the SGID sample when compared 195 
to the corresponding hydrolysate. The RP profile of the hydrophilic fraction of WHP obtained 196 
following SPE is illustrated in Fig. 2C. As expected, this fraction contained peptides which eluted 197 
at low ACN concentrations. SPE did not allow collection of sufficient amounts of the 198 
hydrophobic fraction to allow determination of an IC50 value therefore, IC50 was only determined 199 
for the hydrophilic SPE fraction. 200 
3.2. DPP-IV inhibition with WPH and associated fractions and SGID sample 201 
The DPP-IV IC50 values obtained for the different samples are outlined in Table 1. The IC50 202 
for diprotin A, a well-known inhibitor of DPP-IV activity, was of the same order as previously 203 
reported in other studies (Lacroix & Li-Chan, 2012b; Uenishi et al., 2012). The UF and the 204 
hydrophilic fractions of WPH displayed IC50 values which were significantly different (P <0.05) 205 
from WPH (Table 1). The retentates had significantly higher (P <0.05) IC50 values than the 206 
associated permeates. The IC50 of the 5 kDa permeate (0.95 ± 0.16 mg.mL
-1
) was significantly 207 
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higher (P <0.05) compared to the 2 kDa permeate (0.48 ± 0.11 mg.mL
-1
). The hydrophilic 208 
fraction of WPH had a significantly lower (P < 0.05) IC50 value (1.11 ± 0.09 mg.mL
-1
) than 209 
WPH and its 5 kDa retentate. Subjection of WPH to SGID resulted in a significant decrease (P < 210 
0.05) in the IC50 (1.33 ± 0.17 and 1.02 ± 0.05 mg.mL
-1
 for WPH and its SGID sample, 211 
respectively). The most potent hydrolysate sample/fraction studied was the WPH 2 kDa 212 
permeate. The WPH 2 kDa permeate was approximately 500 times less potent than diprotin A 213 
(Table 1). 214 
Lineweaver and Burk analysis was used to study the mode of DPP-IV inhibition by the 215 
different inhibitors (diprotin A, WPH and its associated UF and hydrophilic fractions and SGID 216 
sample). The double reciprocal plots for WPH, its 5 kDa UF permeate, the hydrophilic fraction 217 
from SPE along with the SGID sample are illustrated in Fig. 3. For all samples studied, there was 218 
no significant difference in Vmax (P ≥ 0.05) without inhibitor or in the presence of inhibitor 219 
(diprotin A, WPH, its associated UF and hydrophilic fractions and SGID sample). In contrast, 220 
Kapp values (Table 1) were significantly different (P < 0.05) from Km values. These results 221 
indicate that WPH and its associated UF fractions and SGID sample all behaved as competitive 222 
inhibitors of DPP-IV (Table 1). 223 
3.3. DPP-IV inhibition in the presence of sitagliptin 224 
The IC50 value for sitagliptin (69 ± 16 nM or 0.036 ± 0.08 ng.mL
-1
- Table 1) was of the same 225 
order as the values previously reported in the literature (Thomas et al., 2008). When sitagliptin 226 
was tested on its own at 0.031 ng.mL
-1
, DPP-IV inhibition was of 59.2 ± 2.7 %. Sitagliptin and 227 
other DPP-IV inhibitors (diprotin A, WPH, Trp-Val and Val-Ala) were combined and presented 228 
to DPP-IV. The dose response curves for diprotin A, WPH, Trp-Val and Val-Ala in the presence 229 
or absence of 0.031 ng.mL
-1
 sitagliptin are illustrated on Fig. 4. The DPP-IV inhibition obtained 230 
with WPH alone and with WPH in the presence of sitagliptin (0.031 ng.mL
-1
) was compared. A 231 
higher inhibition (P < 0.05) was observed with the mixture of sitagliptin and WPH at all WPH 232 
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concentrations studied in comparison to the inhibition seen with WPH alone (Fig. 4B). 233 
Furthermore, the extent of inhibition observed with the mixture of sitagliptin and WPH was 234 
significantly higher (P < 0.05) than 59.2 ± 2.7 % (the extent of DPP-IV inhibition observed with 235 
0.031 ng.mL
-1 
sitagliptin) at all WPH concentrations tested. In the presence of diprotin A, Trp-236 
Val and Val-Ala, the DPP-IV inhibition with 0.031 ng.mL
-1 
sitagliptin was significantly higher (P 237 
< 0.05) only at the lower concentrations studied (Fig 4A, C and D, respectively). This was due to 238 
the fact that the extent of DPP-IV inhibition observed at higher concentrations of diprotin A, Trp-239 
Val and Val-Ala had reached a maximum. Significantly higher DPP-IV inhibition than that 240 
observed with 0.031 ng.mL
-1 
sitagliptin alone was seen with the addition of diprotin A between 241 
1.25 and 12.50 µg.mL
-1
, and Trp-Val and Val-Ala between 0.1×10
-1
 and 0.6 mg.mL
-1
. 242 
Because the extent of DPP-IV inhibition observed with 0.031 ng.mL
-1
 sitagliptin was higher 243 
than 50 %, it was not possible to determine the effect of sitagliptin at this concentration on the 244 
apparent IC50 value of diprotin A, WPH, Trp-Val and Val-Ala. For this reason, the apparent IC50 245 
value of diprotin A, WPH, Trp-Val and Val-Ala was determined in the presence of 0.006 ng.mL
-1
 246 
sitagliptin (Table 2). The extent of DPP-IV inhibition observed with 0.006 ng.mL
-1
 sitagliptin 247 
alone was 39.7 ± 2.0 %. As expected, there was a significant reduction (P < 0.05) in the IC50 248 
value for diprotin A (tested at final concentrations ranging from 12.5 × 10
-3
 to 12.5 µg.mL
-1
) and 249 
WPH, Trp-Val and Val-Ala (tested at final concentrations ranging from 0.6 × 10
-2
 to 0.6 mg.mL
-
250 
1
), in the presence of 0.006 ng.mL
-1
 sitagliptin. The comparable decrease in IC50 value was the 251 
largest with diprotin A (51.8 %) and the lowest with WPH (13.6 %). 252 
4. Discussion 253 
Ingestion of milk proteins, milk-derived peptides and associated amino acids has been shown to 254 
increase insulin secretion in humans (Akhavan, Luhovyy, Brown, Cho, & Anderson, 2010; Frid, 255 
Nilsson, Holst, & Björck, 2005; Geerts et al., 2011; Luhovyy, Akhavan, & Anderson, 2007; 256 
Manders et al., 2006a; Manders et al., 2006b; Morifuji et al., 2010; Power et al., 2009). Previous 257 
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studies have highlighted the role of milk protein hydrolysates and peptides in the inhibition of 258 
DPP-IV (Lacroix & Li-Chan, 2012a; Uchida et al., 2011). The IC50 values described for the whey 259 
protein sample herein are of the same order as values previously reported in the literature. A 1 260 
kDa permeate of a salmon gelatin hydrolysate having an IC50 of 1.35 mg.mL
-1
 (Li-Chan, Hunag, 261 
Jao, Ho, & Hsu, 2012), rice bran hydrolysates with IC50 values of 2.3 ± 0.1 and 26.4 ± 2.3 262 
mg.mL
-1
 (Hatanaka et al., 2012) and amaranth glutelin hydrolysates with IC50 ranging from 1.2 to 263 
2.0 mg.mL
-1
 (Velarde-Salcedo et al., 2013) have been reported. The milk-derived peptide 264 
sequences responsible for DPP-IV inhibition described in the literature are generally di-and tri-265 
peptides (Lacroix & Li-Chan, 2012b), with a molecular mass < 1 kDa. The gel permeation results 266 
herein show that peptides less than 1 kDa represent a relatively high proportion (54.7 %) of 267 
WPH. 268 
UF fractionation of milk-derived hydrolysates with DPP-IV inhibitory properties has 269 
previously been described in the literature where DPP-IV inhibition was higher with some UF 270 
fractions in comparison to the parent hydrolysate (Lacroix & Li-Chan, 2012a). However, the 271 
most potent fractions were not in all cases lower than 1 kDa. For a whey protein hydrolysate, the 272 
fraction between 1 and 3 kDa showed the highest DPP-IV inhibition (Lacroix & Li-Chan, 2012a). 273 
This was explained by the fact that some of the higher molecular weight peptides from whey may 274 
have been substrates for DPP-IV, thereby interfering with hydrolysis of the synthetic substrate 275 
(Gly-Pro-pNA) resulting in an apparently higher extent of inhibition (Lacroix & Li-Chan, 2012a). 276 
It was shown for the UF fractions of a salmon gelatin hydrolysate that a greater DPP-IV 277 
inhibition was observed with the 1 kDa permeate compared to the higher molecular mass 278 
fractions (Li-Chan et al., 2012). The same trend was found herein with the lowest IC50 value 279 
being observed for the WPH 2 kDa permeate (Table 1), which was significantly enriched in 280 
peptides less than 1 kDa (Fig. 1). In agreement with these results, all UF retentates were 281 
significantly less potent than the permeates (Table 1). The hydrophilic fraction of WPH also 282 
showed a significantly lower IC50 value than WPH, suggesting that physicochemical 283 
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characteristics other than the molecular mass of the peptides may play a role in DPP-IV 284 
inhibition. It has been observed that the DPP-IV inhibitory properties of a peptide are governed 285 
by its structure (Hatanaka et al., 2012; Lacroix & Li-Chan, 2012b; Uenishi et al., 2012). 286 
Therefore, peptide composition and structure rather than molecular mass appears to govern the 287 
overall DPP-IV inhibition observed within a particular sample (Lacroix & Li-Chan, 2012a; Li-288 
Chan et al., 2012).  289 
The mode of action of the different samples was studied. From the Lineweaver and Burk 290 
kinetic plots, it was evident that the samples studied behaved as competitive inhibitors of DPP-IV 291 
(Fig. 3). This indicates that the hydrolysate and its associated UF and hydrophilic fractions and 292 
the SGID sample interacted with the active site of the enzyme. It has been shown that diprotin A 293 
(Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) are also substrates for DPP-IV which may explain the 294 
apparent competitive type of inhibition observed with these compounds (Rahfeld, Schierborn, 295 
Hartrodt, Neubert, & Heins, 1991). Lacroix & Li-Chan (2012a) also observed that some milk-296 
derived peptide inhibitors may have structural similarities with DPP-IV substrates and therefore 297 
they may behave as substrates for this enzyme. 298 
SGID of WPH was investigated to study the stability of DPP-IV inhibitory peptides to further 299 
hydrolysis by digestive enzymes. The RP profiles obtained suggest that certain peptides present 300 
in WPH are degraded following SGID (Fig. 2B). The IC50 of the SGID samples was significantly 301 
lower (P < 0.05) than that of WPH (Table 1). Similar results were found in another study where 302 
DPP-IV inhibition with tuna-derived peptides was unaffected or increased following SGID 303 
(Huang, Jao, Ho, & Hsu, 2012). The fact that some low molecular mass peptides may be 304 
responsible for the DPP-IV inhibition observed with WPH is further reinforced by the increase in 305 
potency of the SGID sample. As expected, short peptide sequences can be relatively stable to 306 
SGID. Out of 228 dipeptides studied, Foltz, van Buren, Klaffke & Duchateau (2009) reported that 307 
half of the dipeptides were highly stable to hydrolysis by pancreatic enzymes. The relatively 308 
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small size (< 1 kDa) and the gastrointestinal stability of the bioactive peptides within WPH may 309 
allow them to cross the gut barrier (Foltz et al., 2007; Gardner, 1983; Morifuji et al., 2010). 310 
However, intestinal permeation may not be a limiting factor for the DPP-IV inhibitory activity to 311 
be seen as degradation of incretins such as GIP and GLP-1 occurs directly in the gastrointestinal 312 
tract (Tulipano et al., 2011). The SGID results herein indicate that the DPP-IV inhibitory 313 
properties of WPH may pertain in vivo. 314 
Despite significant differences seen in the IC50 values of the WPH and its associated SGID 315 
sample and fractions, it is likely that in a physiological situation, these differences will not pertain 316 
for certain samples. The IC50 values for WPH, the SGID sample and the fractions of WPH are 317 
relatively high. The IC50 values for WPH is more than 40 times higher than that of Trp-Val and 318 
Val-Ala and more than 900 times higher to that of diprotin A and sitagliptin. Overall, the potency 319 
of WPH and its associated SGID sample and fractions is modest. Therefore it is anticipated that 320 
in vivo, WPH, its associated SGID sample and fractions may display very similar effects in terms 321 
of DPP-IV inhibition. 322 
To our knowledge, no data is currently available in the literature describing the combined 323 
effects of bioactive peptides and drugs on DPP-IV inhibitory properties. DPP-IV inhibition with 324 
different mixtures of whey-derived peptides and sitagliptin was therefore investigated. Trp-Val 325 
and Val-Ala were previously identified as whey-derived DPP-IV inhibitors with IC50 values of 326 
65.69 ± 2.95 and 168.24 ± 7.96 µM, respectively. In addition, Trp-Val was also shown to have 327 
both 2,2-diphenyl-1-picrylhydrazyl (DPPH) and superoxide (SO) scavenging properties and Val-328 
Ala had SO scavenging properties (Nongonierma & FitzGerald, 2013). At all concentrations of 329 
inhibitors (diprotin A, Trp-Val, Val-Ala or WPH) tested in combination with sitagliptin, the DPP-330 
IV inhibition was higher or equal to that of sitagliptin alone. DPP-IV inhibition was significantly 331 
higher (P < 0.05) than that of sitagliptin alone only at the highest concentrations of diprotin A, 332 
Trp-Val and Val-Ala tested. These results suggested that a certain concentration of these peptides 333 
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was required to observe an increased DPP-IV inhibition over that of sitagliptin alone. 334 
Furthermore, it was shown that in the presence of 0.006 ng.mL
-1
 sitagliptin (39.7 ± 2.0 % DPP-IV 335 
inhibition), the apparent IC50 of whey-derived inhibitors was significantly decreased (P < 0.05). 336 
This result suggested that there was a combined additive effect of sitagliptin and whey-derived 337 
peptides on DPP-IV inhibition. The significance of these results needs to be assessed in humans 338 
to determine the implications of these findings for the optimum dosage of sitagliptin for T2D 339 
subjects. 340 
Conclusion 341 
A whey-derived hydrolysate with DPP-IV inhibitory properties has been generated. The 342 
competitive inhibition of DPP-IV observed herein suggests direct interaction by the hydrolysate 343 
and its associated fractions and SGID sample with the active site of DPP-IV. WPH may have 344 
potential as a dietary ingredient with applications in enhancement of the half-life of incretins. 345 
Determination of the bioactive peptide sequences within WPH would allow investigation of the 346 
mode of action of these peptides for their DPP-IV inhibitory properties. Finally, combinations of 347 
sitagliptin with different whey-derived peptides showed an additive DPP-IV inhibition. This may 348 
have implications for an holistic strategy combining a clinical approach, dietary changes and 349 
physical activity in the management of T2D. 350 
351 
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Table 1 Inhibitory concentration inducing 50 % inhibition (IC50) for dipeptidyl peptidase IV (DPP-IV) and type of inhibition determined by Lineweaver 487 
and Burk analysis in the presence of a whey protein hydrolysate (WPH), its associated ultrafiltration and hydrophilic fractions and simulated 488 
gastrointestinal digest (SGID). Values are mean ± confidence interval of triplicate determinations (n=3). 489 
 490 
Compound 
DPP-IV IC50
1
 
(mg.mL
-1
) 
Kapp or Km
2
 
(mM Gly-Pro-pNA) 
WPH 1.33 ± 0.17
g
 1.31* 
WPH- 5 kDa Retentate 1.98 ± 0.35
h
 0.66* 
WPH- 5 kDa Permeate 0.95 ± 0.16
e
 1.36* 
WPH- 2 kDa Retentate 0.72 ± 0.01
d 
0.80* 
WPH- 2 kDa Permeate 0.48 ± 0.01
c
 1.44* 
WPH- hydrophilic 1.11 ± 0.09
f
 1.74* 
WPH- SGID 1.02 ± 0.05
e
 1.44* 
diprotin A 0.001454± 0.000218
b
 1.79* 
sitagliptin 0.000036 ± 0.000008
a
 nd 
No inhibitor na 0.52 
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1
Values represent mean IC50 values ± confidence interval (P = 0.05) for triplicate determination (n=3). Values with different superscript letters are 491 
significantly different (P < 0.05) 492 
2
Kapp value determined using Lineweaver and Burk plots as described in Nongonierma and FitzGerald (2012). *P < 0.05 Kapp (determined in the presence 493 
of inhibitor) vs Km (determined without inhibitor). 494 
na: not applicable 495 
nd: not determined 496 
497 
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Table 2 Apparent inhibitory concentration inducing 50 % inhibition for dipeptidyl peptidase IV (DPP-IV) in the presence of 0.006 mg.mL
-1 
sitagliptin (39.7 498 
± 2.0 % DPP-IV inhibition) and different whey-derived DPP-IV inhibitors and diprotin A. Values are mean ± SD of triplicate determinations (n=3). 499 
Compound 
DPP-IV IC50 Apparent DPP-IV IC50 in the presence 
of 0.006 ng.mL
-1
 sitagliptin
1
 
Reduction in apparent 
IC50 compared to 
inhibitor alone (%)
2,3
 (mg.mL
-1
) (µM) (mg.mL
-1
) (µM) 
diprotin A 0.001454± 0.000218
a
 4.3 ± 0.6
a
 0.000701 ± 0.000013
a 
2.1 ± 0.1
a 
51.8* 
Trp-Val 0.020 ± 0.001
b
 67.5 ± 2.4
b
 0.012 ± 0.001
b 
40.9 ± 1.4
b 
39.4* 
Val-Ala 0.032 ± 0.001
b
 171.3 ± 6.8
c
 0.025 ± 0.001
c 
135.9 ± 1.1
c 
21.0* 
WPH 1.333 ± 0.168
c
 na 1.149 ± 0.051
d
 na 13.6* 
1
Values represent mean IC50 values ± confidence interval (P = 0.05) for triplicate determination (n=3). Within the same column, values with different 500 
superscript letters are significantly different (P < 0.05) 501 
2
 1001 aloneinhibitor   tocompared ICapparent in Reduction 
50
50
50 






IC
nsitagliptiwithICApparent  
502 
3
 *P < 0.05 vs DPP-IV inhibition determined with diprotin A, Trp-Val, Val-Ala or WPH alone. 503 
na: not applicable 504 
 505 
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Figure captions 506 
 507 
Fig. 1. Gel permeation profiles of the unhydrolysed whey proteins (WP), the whey protein 508 
hydrolysate (WPH) and its ultrafiltered 5 and 2 kDa permeates (Perm) and retentates (Ret). 509 
Molecular mass distribution:  : :<1kDa,   : 1-10 kDa and    : >10 kDa. 510 
 511 
Fig. 2. Reverse-phase ultra-performance liquid chromatography (RP-UPLC) of (A) the whey 512 
protein hydrolysate (WPH), (B) its associated simulated gastrointestinal digestion (SGID) sample 513 
and (C) its hydrophilic fraction obtained following solid-phase extraction. 514 
 515 
Fig. 3. Lineweaver and Burk plots of dipeptidyl peptidase IV (DPP-IV) in the presence ()and 516 
absence () of whey protein hydrolysate (WPH) derived inhibitors (A) WPH, (B) WPH 5 kDa 517 
permeate, (C) hydrophilic fraction of WPH and (D) simulated gastrointestinal digest (SGID) of 518 
WPH. Each point represents the mean of 3 values (n=3). 519 
 520 
Fig. 4. Inhibition of dipeptidyl peptidase IV (DPP-IV) by food-derived peptides in the presence 521 
() and absence () of 0.031 ng.mL
-1
 sitagliptin (59.2 ± 2.7 % DPP-IV inhibition) combined with 522 
(A) diprotin A, (B) whey protein hydrolysate (WPH), (C) Trp-Val and (D) Val-Ala. Each point 523 
represents the mean of 3 values (n=3). *: DPP-IV inhibition values determined in the presence 524 
and absence of 0.031 ng.mL
-1
 sitagliptin are significantly different at P < 0.05. 525 
 526 
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